Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 17/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27135558 | 0.81 | MAPT (0.42) | TRPV3CYP1A2POLBMEN1KMT2A | |
| SCHEMBL9300955 | 0.81 | KCNH2 (0.47) | TRPV3MEN1KMT2A | |
| SCHEMBL27285044 | 0.79 | TRPV3 (0.55) | TRPV3CYP1A2MEN1KMT2A | |
| SCHEMBL22130209 | 0.79 | MEN1 (0.41) | TRPV3CYP1A2POLBMEN1KMT2A | |
| SCHEMBL534270 | 0.76 | MEN1 (0.40) | CYP1A2POLBMEN1KMT2A | |
| SCHEMBL19797757 | 0.75 | TRPV3 (0.41) | TRPV3CYP1A2POLB | |
| SCHEMBL23370157 | 0.75 | CYP1A2 (0.39) | TRPV3CYP1A2POLB | |
| SCHEMBL15827603 | 0.73 | TRPV3 (0.46) | TRPV3MEN1KMT2A | |
| SCHEMBL1897204 | 0.73 | SREBF2 (0.43) | CYP1A2POLB | |
| SCHEMBL4882345 | 0.72 | CYP2A6 (0.56) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-103965099-A | Pyridylaminoacetic Acid Compound | UBE INDUSTRIES | 2014-08-06 | — | — | CN | disclosed |
| CN-101970410-B | Pyridylaminoacetic acid compounds | UBE INDUSTRIES | 2014-06-25 | — | — | CN | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | TRPV3 436/4885CYP1A2 159/4885POLB 3280/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | TRPV3 368/4885CYP1A2 220/4885POLB 3560/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | TRPV3 1032/4885CYP1A2 173/4885POLB 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.